全文获取类型
收费全文 | 19117篇 |
免费 | 1299篇 |
国内免费 | 74篇 |
专业分类
耳鼻咽喉 | 217篇 |
儿科学 | 433篇 |
妇产科学 | 354篇 |
基础医学 | 2631篇 |
口腔科学 | 338篇 |
临床医学 | 1650篇 |
内科学 | 4929篇 |
皮肤病学 | 413篇 |
神经病学 | 1678篇 |
特种医学 | 642篇 |
外科学 | 2695篇 |
综合类 | 245篇 |
一般理论 | 8篇 |
预防医学 | 1430篇 |
眼科学 | 421篇 |
药学 | 1143篇 |
中国医学 | 79篇 |
肿瘤学 | 1184篇 |
出版年
2023年 | 133篇 |
2022年 | 331篇 |
2021年 | 557篇 |
2020年 | 309篇 |
2019年 | 454篇 |
2018年 | 533篇 |
2017年 | 352篇 |
2016年 | 373篇 |
2015年 | 456篇 |
2014年 | 629篇 |
2013年 | 853篇 |
2012年 | 1353篇 |
2011年 | 1375篇 |
2010年 | 791篇 |
2009年 | 673篇 |
2008年 | 1135篇 |
2007年 | 1224篇 |
2006年 | 1188篇 |
2005年 | 1116篇 |
2004年 | 1020篇 |
2003年 | 973篇 |
2002年 | 967篇 |
2001年 | 148篇 |
2000年 | 130篇 |
1999年 | 177篇 |
1998年 | 203篇 |
1997年 | 167篇 |
1996年 | 166篇 |
1995年 | 123篇 |
1994年 | 116篇 |
1993年 | 98篇 |
1992年 | 103篇 |
1991年 | 108篇 |
1990年 | 98篇 |
1989年 | 72篇 |
1988年 | 90篇 |
1987年 | 89篇 |
1986年 | 74篇 |
1985年 | 91篇 |
1984年 | 105篇 |
1983年 | 99篇 |
1982年 | 115篇 |
1981年 | 125篇 |
1980年 | 111篇 |
1979年 | 68篇 |
1978年 | 78篇 |
1977年 | 94篇 |
1976年 | 63篇 |
1975年 | 55篇 |
1974年 | 59篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. 总被引:5,自引:0,他引:5
Morris D Groves Vinay K Puduvalli Kenneth R Hess Kurt A Jaeckle Pamela Peterson W K Alfred Yung Victor A Levin 《Journal of clinical oncology》2002,20(5):1383-1388
PURPOSE: Novel therapies are needed for patients with recurrent glioblastoma multiforme (GBM). Because there is evidence that temozolomide (TMZ) has some activity in GBM and is well tolerated, and because of laboratory evidence that metalloproteinases are important in glioma cell invasion, the combination of TMZ and the matrix metalloproteinase inhibitor marimastat (MRM) in patients with recurrent GBM was studied. PATIENTS AND METHODS: Forty-four patients with recurrent GBM after standard radiotherapy were enrolled. For 19 patients, this therapy was their first chemotherapy after tumor progression after irradiation; 25 others had received chemotherapy previously. TMZ 150 to 200 mg/m(2) days 1 to 5 and MRM 50 mg days 8 to 28 was administered at 28-day intervals for two cycles; then patients were reevaluated. Treatment continued until progression of tumor or toxicity developed. RESULTS: Joint and tendon pain was the major therapy-related toxicity and was reported in 47% of patients. Five patients (11%) were removed from the study because of intolerable joint pain. For all patients, the progression-free survival (PFS) at 6 months was 39%. Median PFS was 17 weeks, median overall survival was 45 weeks, and 12-month PFS was 16%. CONCLUSION: The combination of TMZ and MRM resulted in a PFS at 6 months that exceeded the literature target by 29%. This drug combination met phase II study criteria; further study in recurrent patients with GBM might be warranted. Further study of therapy-induced joint pain is necessary. 相似文献
992.
Roger K C Ngan Timothy T C Yip Wai-Wai Cheng John K C Chan William C S Cho Victor W S Ma Kwong-Kee Wan Siu-Kie Au Chun-Key Law Wai-Hon Lau 《Clinical cancer research》2002,8(4):986-994
PURPOSE: The purpose of this work was to study the sera of patients with lymphoepithelioma-like carcinoma (LELC) of the lung for circulating EBV DNA. EXPERIMENTAL DESIGN: Prospectively collected serum samples from five female patients with advanced, inoperable LELC of the lung were measured for free circulating EBV DNA using a quantitative PCR technique. EBV-encoded small RNA (EBER)-1 was assayed in serial serum samples of three of the five patients, either from the start or during the initial phase of chemotherapy/radiotherapy until their terminal event or last follow-up. There was only a single-point sample for analysis in the fourth and fifth patients. Six other patients with LELC of the lung were also retrospectively identified, and their sera were tested for EBER-1 at either the first visit plus the last follow-up visit (n = 2), the first visit only (n = 2), or the last follow-up visit only (n = 2). RESULTS: Prospectively collected serum samples from five patients and retrospectively collected serum samples from two patients who had clinical disease at initial serum measurement showed detectable levels of EBER-1. Retrospectively collected serum samples from four patients with no clinical disease had negative sera. There is consistent correlation between the clinical response to treatment and subsequent clinical course of LELC and serum EBER-1 levels in the three prospective patients with longitudinal serum monitoring. CONCLUSIONS: This study shows for the first time that free EBV DNA can be detected in the serum of patients with LELC of the lung and further suggests the feasibility of its use for monitoring response to therapy in advanced cases. 相似文献
993.
Roland Schnell Oliver Staak Peter Borchmann Christine Schwartz B?rbel Matthey Hinrich Hansen John Schindler Victor Ghetie Ellen S Vitetta Volker Diehl Andreas Engert 《Clinical cancer research》2002,8(6):1779-1786
Ki-4.dgA is an anti-CD30 immunotoxin (IT) constructed by coupling the monoclonal antibody Ki-4 via a sterically hindered disulfide linker to deglycosylated ricin A-chain. This IT was efficacious in vitro and in SCID mice with disseminated human Hodgkin's lymphoma. Accordingly, a Phase I trial in patients (pts) with Hodgkin's lymphoma was designed. The objectives of this Phase I trial were to determine the maximum tolerated dose, the dose-limiting toxicities, pharmacokinetics, and antitumor activity. Seventeen pts with relapsed CD30+ lymphoma were treated with escalating doses (5, 7.5, or 10 mg/m(2)/cycle) of the IT as four bolus infusions on days 1, 3, 5, and 7 for one to three cycles. All of the pts had progressive disease and were heavily pretreated. Nine had primary progressive disease and 14 had advanced disease with massive tumor burdens. The mean age was 35 years (24-52 years). Peak serum concentrations of the intact IT varied from 0.23 to 1.1 microg/ml. Side effects and dose-limiting toxicities were related to vascular leak syndrome, i.e., decreases in serum albumin, edema, weight gain, hypotension, tachycardia, myalgia, and weakness. The maximum tolerated dose was 5 mg/m(2). Seven of 17 (40%) pts made human antiricin antibodies (> or =1.0 microg/ml), and 1 pt developed human antimouse antibodies (> or =1.0 microg/ml). Clinical response in the 15 evaluable pts included 1 partial remission, 1 minor response, and 2 stable diseases. In conclusion, the IT was less well tolerated than other ITs of this type. This might be because of the low number of CD30+ peripheral blood mononuclear cells, and in part because of binding of the IT to soluble CD30 antigen and the resulting circulation of IT/sCD30 complexes. 相似文献
994.
995.
BACKGROUND: Paracetamol (N-acetyl-p-amino-phenol) or acetaminophen has become the most widely used analgesic and antipyretic in children. However, there is a wide discrepancy between the extent to which paracetamol is used and the limited available pharmacological data in small infants. The purpose of this article is to present a review of the current literature regarding the use of paracetamol in neonates and infants with a particular emphasis on pharmacological issues. METHODS: A MEDLINE search (up to March 2000) was conducted to identify relevant English-language publications using paracetamol, children, infants and neonates as search terms. Additional studies were identified from bibliographies of the reviewed literature. RESULTS: Pharmacological studies on paracetamol in infants are few. Most studies have focused on the administration of one single paracetamol dose, and the problem of cumulative toxicity with repeated dosing has not been addressed. Plasma paracetamol concentration should be 10-20 mg ml(-1) to achieve antipyretic and analgesic effects. The bioavailability of the different formulations and routes of administration vary with age. Rectal absorption is slower and more erratic than the oral; however, in the very young, rectal bioavailability is higher than in older patients. Volume of distribution seems to be age-independent, whereas clearance is reduced in neonates and particularly in preterm babies. Neonates and infants are capable of forming the reactive intermediate metabolite that causes hepatocellular damage, particularly after multiple doses. They have an immature glucuronide conjugation system, but the rate constant for the sulphation metabolic pathway is larger than in older children, and this is the most important route of metabolism. CONCLUSIONS: The pharmacokinetics and pharmacodynamics of paracetamol differ substantially in neonates and infants from those in older children and adults; hence, dosing should be adjusted accordingly. 相似文献
996.
Oliver G Lowry A Vernava A Hicks T Burnstein M Denstman F Fazio V Kerner B Moore R Peters W Ross T Senatore P Simmang C Wexner S Wong WD 《Diseases of the colon and rectum》2000,43(9):1194-1200
It should be recognized that these guidelines should not be deemed inclusive of all proper method of care or exclusive of methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific procedure must be made by the physician in light of all of the circumstances presented by the individual patient.Prepared by The Standards Task Force The American Society of Colon and Rectal Surgeons 相似文献
997.
Breast Cancer Research and Treatment - 相似文献
998.
Samuel H. Selesnick John F. Carew Jonathan D. Victor Carl W. Heise Jennifer Levine 《The Laryngoscope》1996,106(5):633-638
The predictive value of intraoperative stimulation thresholds for facial nerve function, using a constant-current system, was examined in 49 patients undergoing resection of cerebellopontine-angle tumors. Immediately after surgery, 75% of the 0.1-mA threshold group, 42% of the 0.2-mA group, and 18% of the 0.3-mA or greater group had good (grade I or II) facial nerve function. One year after surgery, 90% of the 0.1-mA group, 58% of the 0.2-mA group, and 41% of the 0.3-mA or greater group had grade I or II function. A statistically significant breakpoint of 0.2 mA was found to predict good postoperative facial function. Delayed facial paralysis occurred in 22% of patients, but the prognosis for these patients was favorable. Both current stimulation threshold and duration are necessary for a meaningful comparison of data between investigators. Laryngoscope, 106:633-638, 1996 相似文献
999.
Magne Tvinnereim Philip Cole James S. J. Haight Susan Mateika Victor Hoffstein 《The Laryngoscope》1994,104(7):846-849
Computer-assisted open catheter studies of 10 healthy, nose-breathing men in dorsal and in lateral recumbent sleep demonstrated stable intrasubject transpharyngeal differential pressures and airflow resistances. They averaged 19.6 Pa (± standard deviation [SD] 11.9) and 0.103 Pa/cm3 per second (± SD 0.065) in the dorsal posture and stage II sleep during quiet breathing and were not significantly different in the lateral posture or in stage I sleep. Five subjects were snorers, and their pharyngeal airflow pressures and resistances increased substantially during quiet breathing on assumption of recumbency and much more in sleep. In the 5 subjects who were nonsnorers, postural changes were not significant and sleep increases were moderate. During snoring, transpharyngeal pressures and resistances increased even further, averaging 188 Pa and 1.02 Pa/cm3 per second for the whole group. Transpharyngeal differential pressures and hypopharyngeal transmural pressures frequently exceeded 300 Pa in inspiration and in expiration during periods of snoring. Yet, transpharyngeal differential pressures and resistances did not reveal appreciable differences between phases that would indicate compliant change of pharyngeal cross section. Breathing frequency was unchanged, but ventilation was significantly diminished at elevated upper airway resistances (P<.01). Transpharyngeal resistances and differential pressures varied independently from widely differing nasal resistances. As with our earlier studies, pressure measurements alone clearly demonstrated breathing patterns and events. 相似文献
1000.
INTRAVASCULAR COAGULATION DURING PREGNANCY AND THE PUERPERIUM 总被引:2,自引:0,他引:2